Drug pricing is already an issue in the U.S. election campaign. Brian Abrahams, MD and Head of Biotech Research at RBC Capital Markets joins the Pathfinders in Biopharma podcast to consider how this, together with other policy developments in the U.S. and worldwide, might affect a resurgent biotech sector.